Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono

Rather than financial considerations, Ono Pharmaceutical will receive co-development and co-commercialization rights to rheumatoid arthritis drug Orencia in Japan.